Bollard Group LLC Takes $360,000 Position in Magenta Therapeutics Inc (MGTA)

Bollard Group LLC purchased a new position in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 30,000 shares of the company’s stock, valued at approximately $360,000. Bollard Group LLC owned approximately 0.09% of Magenta Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MGTA. Dean Capital Investments Management LLC acquired a new stake in shares of Magenta Therapeutics in the 2nd quarter valued at approximately $558,000. BlackRock Inc. acquired a new stake in shares of Magenta Therapeutics in the 2nd quarter valued at approximately $1,350,000. Tiverton Asset Management LLC acquired a new stake in shares of Magenta Therapeutics in the 2nd quarter valued at approximately $125,000. Citadel Advisors LLC acquired a new stake in shares of Magenta Therapeutics in the 2nd quarter valued at approximately $1,172,000. Finally, Harvard Management Co. Inc. acquired a new stake in shares of Magenta Therapeutics in the 2nd quarter valued at approximately $4,490,000. 30.31% of the stock is owned by institutional investors.

Separately, Zacks Investment Research raised Magenta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Magenta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $19.33.

NASDAQ MGTA opened at $7.17 on Friday. Magenta Therapeutics Inc has a 12 month low of $6.10 and a 12 month high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.18. On average, equities research analysts predict that Magenta Therapeutics Inc will post -3.19 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Bollard Group LLC Takes $360,000 Position in Magenta Therapeutics Inc (MGTA)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2018/11/16/bollard-group-llc-takes-360000-position-in-magenta-therapeutics-inc-mgta.html.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Featured Article: What is the NASDAQ?

Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply